End Stage Kidney Disease, Fibrosis Myocardial
Conditions
Keywords
Cardiac MRI, Hemodialysis, Myocardial Fibrosis, Myocardial Inflammation
Brief summary
There are currently no good ways of measuring levels of scarring in the hearts of patients with advanced kidney disease and patients on dialysis, although recent research has shown a new cardiac MRI technique, called native T1 mapping, may provide a solution to this. To assess the accuracy of this novel technique in dialysis patients, it is essential to undertake a study which compares native T1 mapping to actual levels of scarring in the hearts of patients on dialysis.
Detailed description
Native T1 mapping is a novel, non-contrast, cardiac MRI technique that characterises myocardial tissue by exploiting the different water content of tissues. It correlates well with histo-pathological levels of myocardial fibrosis in diseases of pressure overload such as aortic stenosis. There is growing evidence to demonstrate the potential of native T1 mapping as an imaging biomarker of myocardial fibrosis in patients with ESRD; myocardial native T1 values are higher in patients with ESRD than controls, and associate with measures of myocardial strain and circulating markers of cardiac dysfunction. Although native T1 times are affected by water content of tissues, our group has shown that native T1 times are not influenced by clinical changes in fluid status in HD patients and that the inter-study reproducibility and intra- and inter-observer variability of native T1 are outstanding. Native T1 mapping is a promising, non-invasive imaging biomarker of myocardial fibrosis in patients with advanced renal disease. It is essential that the technique is validated against histology before further use in clinical studies. The aim of this study is to directly assess the relationship between native T1 mapping and levels of MF examined at post-mortem in haemodialysis patients.
Interventions
DIAGNOSTIC_TESTCardiac MRI scan
A non-contrast cardiac MRI (CMR) scan at 3-Tesla platform (Skyra, Siemens Medical Imaging, Erlangen, Germany). This non-contrast CMR scan will principally determine: Left ventricular (LV) mass and volumes/ejection fraction and; fibrosis using T1 mapping.
DIAGNOSTIC_TESTEchocardiogram
Assessments will include: LV size and function as per the American Society of Echocardiography guidelines. In addition specific focus will be paid end-diastolic integrated backscatter measurements.
PROCEDURECardiac explantation
A limited post-mortem will be performed to retrieve patients' hearts for preparation and storage at St George's University, London where direct comparison will be made between levels of scarring seen directly under the microscope between that on the MRI scans.
DIAGNOSTIC_TEST48-Hour continuous cardiac monitoring
Attach continuous Holter monitor (Schiller, medilog®AR12 plus/AR4 plus/FD5 plus, Baar, Switzerland) that will start before dialysis and terminate just before the subsequent dialysis treatment 48h later.
DIAGNOSTIC_TESTBlood samples
Collect blood samples from the arterial needle before dialysis. Approximately 30 millilitres of blood will be collected and then be pipetted into cryotubes and frozen at -80°C in an electronically monitored freezer for analysis in batches throughout the study. These samples will be used to investigate the relationship between circulating biomarkers of fibrosis, the MRI scans and the histological samples.
Sponsors
University Hospitals, Leicester
St George's, University of London
University of Leicester
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Prevalent haemodialysis patient (more than 3 months) * Active on the supportive care register with anticipated death in the subsequent 12 months * Able to give informed consent * Consent to donation of heart for research following death * Able to understand written and verbal explanations in English
Exclusion criteria
* Contraindication to MRI scan (e.g. pacemaker, incompatible metallic implants, claustrophobia) * Patients with expected or potential infiltrative cardiomyopathy (e.g. amyloidosis) * Unable to give informed consent * Unable to understand written and verbal explanations in English
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between MRI and histological measures of cardiac fibrosis | Cardiac MRI performed within 12-months of histological samples obtained post-mortem | To assess the correlation between native T1 values measured using cardiac MRI in haemodialysis patients approaching the end of their lives, with histological samples analysed post-mortem. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Accuracy of MRI versus ECHO in the measurement of cardiac fibrosis | Echocardiograms performed within 12-months of histological samples obtained post-mortem | Relationship between integrated backscatter (measured with echocardiography) and levels of myocardial fibrosis on histology measured at post-mortem. |
| Relationship between cardiac fibrosis and heart rhythm | Continuous Holter recording performed within 12-months of histological samples obtained post-mortem | Relationship between continuous Holter-monitor data and levels of myocardial fibrosis on histology measured at post-mortem. |
| Correlation between cardiac fibrosis and relevant circulating biomarkers | Samples collected within 12-months of histological samples obtained post-mortem | Relationship between humoral markers of cardiac dysfunction of fibrosis and levels of myocardial fibrosis on histology measured at post-mortem |
| Additional cardiac MRI techniques and the measurement of cardiac fibrosis | Cardiac MRI performed within 12-months of histological samples obtained post-mortem | The relationship between additional, non-contrast CMR techniques and histology at post-mortem |
Countries
United Kingdom
Contacts
Primary ContactJames Burton, DM, FRCP
Backup ContactMatthew Graham-Brown, MBChB, MRCP
Outcome results
None listed